Q: DOCS; As I understand matters while this issue reported very good progress in its last earnings statement the investment community seems luke warm so I wondered what contributed to their last earnings and whether the improvement was durable, or not, while on TMDX the projections are quite aggressive against the backdrop of a poor quarter, so once again I am curious as to what triggered their poor performance in the last reported quarter and whether the service they offer is unique or copied/ replicated by others. Look forward to your response.
Q: Forward metrics for LLY and NVO show roughly the same revenue growth, but LLY shows much better earnings and ROE growth. What, then, is the case for recommending both (other than that the market is big enough for both to appreciate)? I realize that, for drug developers, depth of pipeline and patent expiry are also factors, but for simplicity have assumed that, in these respects, their situations and risks are comparable - in which case, shouldn't things like ROE growth turn out to be decisive?
Q: I'm planning on purchasing some additional US investments in my RRSP. I already own QQQ, which represents approximately 38% of my US holdings. I was planning on dividing the remaining 62% between SPY and VTI. I'm described as a growth investor with a 5-7 time horizon before possibly beginning withdrawals. May I get your thoughts on this division? Should I consider cutting back on QQQ to redistribute to the other two? The US represents 45% of my overall RRSP holdings.
Q: Team, I have holdings in all three and although I have done great with BDX over the years, it seems to be struggling. I am thinking of selling but would like your comments on increasing my holdings in SYK and ISRG or would you provide insights another option. All three stocks are in my non registered account.
By the way, because of your insights on AMED of a few years ago, I sold the stock and purchased GOOG.............it was a great move
I have whittled down my holdings to 15 stocks and want to be careful adding more
Q: Hi,
Is SMCI a buy today? How would you approach the outcome of an independent review? Does it mean the financial reports and projected growth are intact?
Regards.
Q: You seem to be recommending these three stocks in some of your recent replies. Can you please rank them in order of highest projected or potentially growth over the next three or four years, as well as suitable entry prices? I appreciate your time.
Q: good morning - I have done well adding to VOO over the past two years. I recently took a position in IWO, anticipating a broader economic increase. What do you think about pruning VOO and adding to IWO? Or adding to a different US ETF?
Q: Watching Bermans call. He suggests the midcap space in the US will flourish with Trump.
I have done quite well with VUN. What is your opinion re the large cap space vs the midcaps in the next 4 years.
Do you think this is so and with extra cash in my RRSP, would you just stick with the large cap ETF or go with the small cap ETF.
Which of the large cap ETF would you choose, VFV with a lower MER over VUN?
Is XMC your choice for the mid cap ETF?
Q: Hello, I am looking to buy one of these stocks for a 5+ year term. Which order would you buy (most conviction to least) and at what entry point ?
I have funds in both US and CA TFSA accounts, so, it is not a big consideration.
Q: Hi,
Could I please have you take on the stock performance of Regeneron Pharmaceuticals over the last year or so and its future prospects?
Thank you, Michael